Celcuity announces US launch of FDA-approved breast cancer drug REVTORPYK

Celcuity Inc. announced that REVTORPYK (gedatolisib), an FDA-approved breast cancer therapy, is commercially available in the US. The launch follows recent regulatory approvals and positions the company in the advanced breast cancer market.